Preclinical evaluation of efficacy and stability of docetaxel micelle-encapsulated by a tripodal cyclotriphosphazene amphiphile

Song Wha Chae; Yong Joo Jun; Jin Xin Cui; Jung Hyun Park; Hwa Jeong Lee; Youn Soo Sohn

doi:10.1016/j.biopha.2014.04.002

Preclinical evaluation of efficacy and stability of docetaxel micelle-encapsulated by a tripodal cyclotriphosphazene amphiphile

Song Wha Chae, Yong Joo Jun, Jin Xin Cui, Jung Hyun Park, Hwa Jeong Lee, Youn Soo Sohn

Department of Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Docetaxel formulated by micelle-encapsulation using a tripodal cyclotriphosphazene amphiphile [NP(MPEG750)(GlyPheLeu)₂Et]₃ (CP750) was named "Phostaxel" and compared in efficacy and stability with Taxotere^® formulated using the surfactant polysorbate 80, which is currently in clinical use. Phostaxel has always shown better efficacy than Taxotere^® in various xenograft trials at the same dosage and administration schedule against the tumor cell lines tested. The better efficacy of Phostaxel could be explained based on the difference in pharmacokinetic and biodistribution profiles of Phostaxel and Taxotere^®. Phostaxel exhibited significantly slower clearance rate and larger AUC_last value compared with Taxotere^®. Phostaxel has also shown higher DTX distribution in tumor than Taxotere^®. In addition, Phostaxel displayed better solution stability compared with Taxotere^® both in distilled water and in saline solution at room and refrigerator temperatures.

Original language	English
Pages (from-to)	649-655
Number of pages	7
Journal	Biomedicine and Pharmacotherapy
Volume	68
Issue number	5
DOIs	https://doi.org/10.1016/j.biopha.2014.04.002
State	Published - Jun 2014

Bibliographical note

Funding Information:
This study was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea ( HI11C0532 ) and by National Research Foundation of Korea (NRF) Grant funded by the Korean Government (MEST) ( NRF-2011-0013493 ).

Keywords

Anticancer drug
Cyclotriphosphazene
Docetaxel
Drug delivery
Polymeric micelle

Access to Document

10.1016/j.biopha.2014.04.002

Cite this

@article{0107e63a8f8d4ab4bc09fbea6a4bf80f,

title = "Preclinical evaluation of efficacy and stability of docetaxel micelle-encapsulated by a tripodal cyclotriphosphazene amphiphile",

abstract = "Docetaxel formulated by micelle-encapsulation using a tripodal cyclotriphosphazene amphiphile [NP(MPEG750)(GlyPheLeu)2Et]3 (CP750) was named {"}Phostaxel{"} and compared in efficacy and stability with Taxotere{\textregistered} formulated using the surfactant polysorbate 80, which is currently in clinical use. Phostaxel has always shown better efficacy than Taxotere{\textregistered} in various xenograft trials at the same dosage and administration schedule against the tumor cell lines tested. The better efficacy of Phostaxel could be explained based on the difference in pharmacokinetic and biodistribution profiles of Phostaxel and Taxotere{\textregistered}. Phostaxel exhibited significantly slower clearance rate and larger AUClast value compared with Taxotere{\textregistered}. Phostaxel has also shown higher DTX distribution in tumor than Taxotere{\textregistered}. In addition, Phostaxel displayed better solution stability compared with Taxotere{\textregistered} both in distilled water and in saline solution at room and refrigerator temperatures.",

keywords = "Anticancer drug, Cyclotriphosphazene, Docetaxel, Drug delivery, Polymeric micelle",

author = "Chae, {Song Wha} and Jun, {Yong Joo} and Cui, {Jin Xin} and Park, {Jung Hyun} and Lee, {Hwa Jeong} and Sohn, {Youn Soo}",

note = "Funding Information: This study was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea ( HI11C0532 ) and by National Research Foundation of Korea (NRF) Grant funded by the Korean Government (MEST) ( NRF-2011-0013493 ).",

year = "2014",

month = jun,

doi = "10.1016/j.biopha.2014.04.002",

language = "English",

volume = "68",

pages = "649--655",

journal = "Biomedicine and Pharmacotherapy",

issn = "0753-3322",

publisher = "Elsevier Masson s.r.l.",

number = "5",

}

TY - JOUR

T1 - Preclinical evaluation of efficacy and stability of docetaxel micelle-encapsulated by a tripodal cyclotriphosphazene amphiphile

AU - Chae, Song Wha

AU - Jun, Yong Joo

AU - Cui, Jin Xin

AU - Park, Jung Hyun

AU - Lee, Hwa Jeong

AU - Sohn, Youn Soo

N1 - Funding Information: This study was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea ( HI11C0532 ) and by National Research Foundation of Korea (NRF) Grant funded by the Korean Government (MEST) ( NRF-2011-0013493 ).

PY - 2014/6

Y1 - 2014/6

N2 - Docetaxel formulated by micelle-encapsulation using a tripodal cyclotriphosphazene amphiphile [NP(MPEG750)(GlyPheLeu)2Et]3 (CP750) was named "Phostaxel" and compared in efficacy and stability with Taxotere® formulated using the surfactant polysorbate 80, which is currently in clinical use. Phostaxel has always shown better efficacy than Taxotere® in various xenograft trials at the same dosage and administration schedule against the tumor cell lines tested. The better efficacy of Phostaxel could be explained based on the difference in pharmacokinetic and biodistribution profiles of Phostaxel and Taxotere®. Phostaxel exhibited significantly slower clearance rate and larger AUClast value compared with Taxotere®. Phostaxel has also shown higher DTX distribution in tumor than Taxotere®. In addition, Phostaxel displayed better solution stability compared with Taxotere® both in distilled water and in saline solution at room and refrigerator temperatures.

AB - Docetaxel formulated by micelle-encapsulation using a tripodal cyclotriphosphazene amphiphile [NP(MPEG750)(GlyPheLeu)2Et]3 (CP750) was named "Phostaxel" and compared in efficacy and stability with Taxotere® formulated using the surfactant polysorbate 80, which is currently in clinical use. Phostaxel has always shown better efficacy than Taxotere® in various xenograft trials at the same dosage and administration schedule against the tumor cell lines tested. The better efficacy of Phostaxel could be explained based on the difference in pharmacokinetic and biodistribution profiles of Phostaxel and Taxotere®. Phostaxel exhibited significantly slower clearance rate and larger AUClast value compared with Taxotere®. Phostaxel has also shown higher DTX distribution in tumor than Taxotere®. In addition, Phostaxel displayed better solution stability compared with Taxotere® both in distilled water and in saline solution at room and refrigerator temperatures.

KW - Anticancer drug

KW - Cyclotriphosphazene

KW - Docetaxel

KW - Drug delivery

KW - Polymeric micelle

UR - http://www.scopus.com/inward/record.url?scp=84905082523&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2014.04.002

DO - 10.1016/j.biopha.2014.04.002

M3 - Article

C2 - 24930885

AN - SCOPUS:84905082523

SN - 0753-3322

VL - 68

SP - 649

EP - 655

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

IS - 5

ER -

Preclinical evaluation of efficacy and stability of docetaxel micelle-encapsulated by a tripodal cyclotriphosphazene amphiphile

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this